Now Location：Home--About Us--Core team
Dr. Chen Zhaoyuan, Technical Advisor Ph.D. from the University of North Texas, member of the American Society of Sciences, member of the American Society of Microbiology, and member of the Johns Hopkins Medical and Surgical Association. He has won multiple awards, including the Tri beta National Biological Science Award, the PHI BETA DELTA International Organization Outstanding International Scholar Award, and the 2000 National Leadership Award from the Republican Congressional Committee in the United States. Dr. Chen is one of the earliest scientists internationally to study the cellular signaling pathways and DNA damage in cancer. He has received multiple research grants from the US National Institutes of Health (NIH) and the US Department of Energy, and his related achievements have been published in well-known academic journals such as Science, PNAS, and CancerResearch. After retiring as a postdoctoral fellow at the Cancer Center of Johns Hopkins University School of Medicine in 1995, he served as a Distinguished Professor in the Department of Biology at the University of Texas in the United States, and also served as the Director of Research and Development at the renowned Biosynthesis Inc. in the United States. In 1999, Texas Biogene Inc. was founded with an academic background in the field of molecular immunology, and was one of the earliest in the world to develop HLA (human leukocyte antigen) genotyping reagents (mainly used for pre transplant typing and disease-related research). The products have excellent performance and are widely praised, and are sold worldwide.
General Manager Wang Hao In 2010, he obtained a Master's degree in Molecular Biology and Biological Industry Management from the University of Orleans in France, a Bachelor's degree in Biotechnology from Shanghai Ocean University, and was awarded the "Double Innovation Plan" talent in Jiangsu Province, the "333 Talent" talent in Jiangsu Province, and the "113 Plan" talent in Taizhou. He was also a senior engineer. From 2004 to 2006, he worked at the Texas biogene. INC China office in the United States. TBG is one of the earliest and only companies in the world to provide transplant immune matching reagents, and its products are widely sold worldwide. During his time at TBG, he successively served as technical support and regional manager in southern China, independently developing dozens of tertiary hospitals and blood centers in central and southern China. After returning to China in 2010, he worked in the field of molecular diagnosis. Product development and sales. Established Jiangsu Weihe Biotechnology Co., Ltd. in March 2014.
